The systemic actions of two other biological psoriasis management options, namely adalimumab and etanercept, were investigated Campanati et al. At the end of 12 weeks of therapy with one of these medications, it was observed that vascular endothelial growth factor production decreased significantly (p < 0.05), with adalimumab exerting a more notable effect in reducing this variable. Here, VEGFA is linked to psoriasis.